Pretreatment direct bilirubin and total cholesterol are significant predictors of overall survival in advanced non-small-cell lung cancer patients with EGFR mutations

Cancer statistics, 2016

(2016) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Characteristics and overall survival of EGFR mutation-positive non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors: a retrospective analysis for 1660 Japanese patients

(2016) Akira Inoue et al.   JAPANESE JOURNAL OF CLINICAL ONCOLOGY

Prognostic factors for progression-free and overall survival in advanced biliary tract cancer

(2015) J. Bridgewater et al.   ANNALS OF ONCOLOGY

Elevated serum bilirubin levels are associated with improved survival in patients with curatively resected non-small-cell lung cancer

(2015) Ning Li et al.   Cancer Epidemiology

Afatinib versus cisplatin plus pemetrexed in Japanese patients with advanced non-small cell lung cancer harboring activatingEGFRmutations: Subgroup analysis of LUX-Lung 3

(2015) Terufumi Kato et al.   CANCER SCIENCE

Dexmedetomidine Attenuates Bilirubin-Induced Lung Alveolar Epithelial Cell Death In Vitro and In Vivo*

(2015) Jian Cui et al.   CRITICAL CARE MEDICINE

The 2015 World Health Organization Classification of Lung Tumors

(2015) William D. Travis et al.   Journal of Thoracic Oncology

Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials

(2015) James Chih-Hsin Yang et al.   LANCET ONCOLOGY

Prognostic significance of pretreatment serum levels of albumin, LDH and total bilirubin in patients with non-metastatic breast cancer

(2014) Xiaoan Liu et al.   CARCINOGENESIS

The Ability of Bilirubin in Identifying Smokers with Higher Risk of Lung Cancer: A Large Cohort Study in Conjunction with Global Metabolomic Profiling

(2014) C.-P. Wen et al.   CLINICAL CANCER RESEARCH

Body mass index, cholesterol level and risk of lung cancer in Lithuanian men

(2014) Rūta Everatt et al.   LUNG CANCER

High-Density Lipoprotein Cholesterol Is a Favorable Prognostic Factor and Negatively Correlated with C-Reactive Protein Level in Non-Small Cell Lung Carcinoma

(2014) Pei-Dong Chi et al.   PLoS One

Combined Effects of Smoking and Bilirubin Levels on the Risk of Lung Cancer in Korea: The Severance Cohort Study

(2014) Jung-eun Lim et al.   PLoS One

Quantification of Excision Repair Cross-Complementing Group 1 and Survival in p16-Negative Squamous Cell Head and Neck Cancers

(2013) R. Mehra et al.   CLINICAL CANCER RESEARCH

PARAMOUNT: Final Overall Survival Results of the Phase III Study of Maintenance Pemetrexed Versus Placebo Immediately After Induction Treatment With Pemetrexed Plus Cisplatin for Advanced Nonsquamous Non–Small-Cell Lung Cancer

(2013) Luis G. Paz-Ares et al.   JOURNAL OF CLINICAL ONCOLOGY

The role of cholesterol metabolism and cholesterol transport in carcinogenesis: a review of scientific findings, relevant to future cancer therapeutics

(2013) Pedro M. R. Cruz et al.   Frontiers in Pharmacology

Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin–paclitaxel for chemo-naïve non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002)

(2012) A. Inoue et al.   ANNALS OF ONCOLOGY

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

(2012) Rafael Rosell et al.   LANCET ONCOLOGY

Association of Serum Bilirubin with Contrast-Induced Nephropathy and Future Cardiovascular Events in Patients Undergoing Coronary Intervention

(2012) Shao-Sung Huang et al.   PLoS One

Role of Cholesterol in the Development and Progression of Breast Cancer

(2011) Gemma Llaverias et al.   AMERICAN JOURNAL OF PATHOLOGY

Possibility of multivariate function composed of plasma amino acid profiles as a novel screening index for non-small cell lung cancer: a case control study

(2011) Jun Maeda et al.   BMC CANCER

Serum Bilirubin and Risk of Respiratory Disease and Death

(2011) Laura J. Horsfall   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non–Small-Cell Lung Cancer in Asia (IPASS)

(2011) Masahiro Fukuoka et al.   JOURNAL OF CLINICAL ONCOLOGY

A metabolomic approach to lung cancer

(2011) Suya Hori et al.   LUNG CANCER

Lipid raft localization of EGFR alters the response of cancer cells to the EGFR tyrosine kinase inhibitor gefitinib

(2010) Mary E. Irwin et al.   JOURNAL OF CELLULAR PHYSIOLOGY

Baseline and On-Treatment High-Density Lipoprotein Cholesterol and the Risk of Cancer in Randomized Controlled Trials of Lipid-Altering Therapy

(2010) Haseeb Jafri et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Prediagnostic Total and High-Density Lipoprotein Cholesterol and Risk of Cancer

(2009) J. Ahn et al.   CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION

Comparison of squamous cell carcinoma and adenocarcinoma of the lung by metabolomic analysis of tissue–serum pairs

(2009) K.W. Jordan et al.   LUNG CANCER

Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma

(2009) Tony S. Mok et al.   NEW ENGLAND JOURNAL OF MEDICINE

Preoperative total serum cholesterol as a prognostic factor for survival in patients with resectable non-small-cell lung cancer

(2009) Mihael Sok et al.   WIENER KLINISCHE WOCHENSCHRIFT

Lung Cancer

(2008) Roy S. Herbst et al.   NEW ENGLAND JOURNAL OF MEDICINE